KRUNJA / SHUTTERSTOCK.COM
Over the past few years China’s life sciences sector has become a hive of activity as specialist IP courts have been implemented and M&A activity has ramped up. LSIPR assesses some of these developments.
In 2014, three specialist intellectual property courts were established in Beijing, Shanghai and Guangzhou.
Within eight months, the courts had received more than 10,000 lawsuits and decided 4,160 cases, according to a press conference by the Supreme People’s Court of China, reported on by Lee and Li Attorneys-at-Law.
James Zhu, partner at law firm JunHe, applauds the progress made by the Chinese courts in the IP arena over the past few years.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Eli Lilly, Roche, life sciences, Chinese Food and Drug Administration, IP enforcement, M&A, patent, licensing, GE Healthcare,